LDS

Company Overview

Snapshot

Founded in January 2012 by Nissim Garti, Prof. and Sharon Garti-Levi, PhD, LDS operates with 1–10 employees. The company specializes in drug delivery systems and in December 2016 secured a marketing deal for a medical cannabis product, demonstrating its technology's commercial applicability.

Business overview

LDS, also known as Lyotropic Delivery Systems, is a biotechnology company focused on developing advanced drug delivery solutions using liquid nano-sized systems. Its proprietary technology enhances the transport of poorly absorbed macromolecules across the gastrointestinal wall to the bloodstream without altering therapeutic compounds. This is achieved through modified soft and fluid gel mesophases, which are thermodynamically stable and offer a long shelf life. LDS serves the pharmaceutical and life sciences industries, with a portfolio spanning oral, ocular, and transdermal applications, creating new uses for both generic and innovative drugs using safe, FDA-recognized components.

Strategic signal

In December 2016, LDS Biotech signed a marketing agreement with US distributor Ananda to develop a medical cannabis product. This partnership is significant as it validates LDS's drug delivery technology for extracting the CBD component from cannabis, enabling oral administration. The deal projected annual revenues exceeding $10 million for Ananda, with a percentage going to LDS, signaling strong commercial potential and market entry for the company's innovative delivery systems in the rapidly expanding medical cannabis sector.

Company Intelligence Q&A

What is LDS's core technology?

LDS develops drug delivery systems based on liquid nano-sized delivery systems. Its proprietary technology enables solubilizing large loads of poorly absorbed macromolecules, enhancing their transport across the gastrointestinal wall to the bloodstream without modifying the therapeutic compounds.

When was LDS founded and by whom?

LDS was founded in January 2012 by Nissim Garti, Prof. and Sharon Garti-Levi, PhD.

What significant partnership did LDS secure in December 2016?

In December 2016, LDS Biotech signed an agreement with US distributor Ananda to use its technology as the basis for a medical cannabis product. Ananda estimated its annual revenue from this product would exceed $10 million, with a percentage given to LDS.

What types of applications does LDS's technology support?

LDS's portfolio comprises a range of projects including oral, ocular, and transdermal applications, creating new uses for generic or innovative drugs.

What is the basis of LDS's mesophase technology?

LDS's approach is based on the formation of modified soft and fluid gel mesophases with characteristics between a liquid and a crystal. These mesophases are composed of water nano-channels packed in unique symmetries, which are thermodynamically stable at various temperatures, resulting in a long shelf life.